Narcolepsy 1; Nrclp1
Description
Adie (1926) first delineated narcolepsy as a separate and specific entity. It is a sleep disorder characterized by attacks of disabling daytime drowsiness and low alertness. The normal physiologic components of rapid eye movement (REM) sleep, dreaming and loss of muscle tone, are separated and also occur while the subject is awake, resulting in half-sleep dreams and episodes of skeletal muscle paralysis and atonia (cataplexy and sleep paralysis). Unlike normal sleep, that of narcolepsy often begins with REM activity and the time taken to fall asleep is shorter than normal.In contrast to animal models, human narcolepsy is not a simple genetic disorder. Most human cases of narcolepsy are sporadic and carry a specific HLA haplotype (Peyron et al., 2000). Familial cases are the exception rather than the rule, and monozygotic twins show only partial concordance (25 to 31%) (Mignot, 1998).
Genes related to Narcolepsy 1; Nrclp1
- HCRT
Clinical Features
Top most frequent phenotypes and symptoms related to Narcolepsy 1; Nrclp1
- Neoplasm
- Nevus
- Tics
- Hyperactivity
- Gliosis
- Paralysis
- Hallucinations
- Brain neoplasm
- Hypersomnia
- Cataplexy
Incidence and onset information
— Not enough data available about incidence and published cases.
Accelerate your rare disease diagnosis with us
Narcolepsy 1; Nrclp1 Recommended genes panels
Panel Name, Specifity and genes Tested/covered |
---|
Narcolepsy 1 (sequence analysis of HCRT gene).
By CGC Genetics in Portugal.
HCRT
Specificity
100 %
Genes
100 % |
Narcolepsy.
By Centogene AG - the Rare Disease Company in Germany.
HCRT
Specificity
100 %
Genes
100 % |
Single gene testing HCRT.
By CeGaT GmbH in Germany.
HCRT
Specificity
100 %
Genes
100 % |
HCRT.
By Fulgent Genetics Fulgent Genetics in United States.
HCRT
Specificity
100 %
Genes
100 % |
Alternate names
Narcolepsy 1; Nrclp1 Is also known as narcoleptic syndrome 1.
If you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like FOCAL SEGMENTAL GLOMERULOSCLEROSIS 3, SUSCEPTIBILITY TO; FSGS3 KALLMANN SYNDROME CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMAL NEVI TYLOSIS WITH ESOPHAGEAL CANCER; TOC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1 CROUZON SYNDROME ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4A; ARCI4A